What antiplatelet regimen should be started after brachial artery thrombectomy for a patient with brachial artery thrombosis?

Antiplatelet Therapy After Brachial Artery Thrombectomy

Start dual antiplatelet therapy (DAPT) with aspirin 75–100 mg daily plus clopidogrel 75 mg daily immediately after brachial artery thrombectomy, continuing for at least 1–6 months, then transition to single antiplatelet therapy indefinitely.

Immediate Post-Thrombectomy Management

Initiate DAPT as soon as hemostasis is secured, ideally within 24 hours of the procedure 1, 2. The combination of aspirin and clopidogrel provides superior protection against re-thrombosis in the acute post-intervention period compared to single antiplatelet therapy 1, 2.

Loading Dose Strategy

• Administer clopidogrel 300 mg loading dose at the time of or immediately after thrombectomy to achieve rapid platelet inhibition 1, 3
• Give aspirin 160–325 mg loading dose if the patient was not already on aspirin 1
• Loading doses accelerate the onset of antiplatelet effect, which is critical in the immediate post-thrombectomy window when re-thrombosis risk is highest 1, 3

Maintenance Therapy Dosing

• Aspirin 75–100 mg daily (not 325 mg) to minimize bleeding risk while maintaining efficacy 1, 4
• Clopidogrel 75 mg daily as the P2Y12 inhibitor of choice 1, 3
• Avoid ticagrelor or prasugrel in this setting, as clopidogrel has the most favorable safety profile for peripheral arterial interventions 3, 5

Duration of Dual Antiplatelet Therapy

Continue DAPT for 1–6 months after brachial artery thrombectomy, with the specific duration determined by bleeding risk assessment 1. This recommendation is extrapolated from peripheral artery disease (PAD) revascularization guidelines, as brachial artery thrombectomy represents an acute arterial intervention analogous to lower extremity revascularization 1.

Risk-Stratified Duration

• High bleeding risk patients: Consider shortening DAPT to 1 month, then transition to single antiplatelet therapy 1
• Standard risk patients: Continue DAPT for 3–6 months 1, 6
• High thrombotic risk (recurrent thrombosis, extensive clot burden, incomplete flow restoration): Extend DAPT toward 6 months 1, 6

Transition to Long-Term Single Antiplatelet Therapy

After completing the DAPT course, transition to single antiplatelet therapy indefinitely to reduce long-term cardiovascular and limb event risk 1.

Preferred Single Agent

• Clopidogrel 75 mg daily is preferred over aspirin for long-term secondary prevention in symptomatic peripheral arterial disease 1
• Aspirin 75–100 mg daily is an acceptable alternative if clopidogrel is contraindicated or not tolerated 1

Bleeding Risk Mitigation

Prescribe a proton pump inhibitor (PPI) during DAPT to reduce gastrointestinal bleeding risk 1, 3, 4.

• Use pantoprazole or rabeprazole rather than omeprazole/esomeprazole, as the latter may reduce clopidogrel's antiplatelet effect through CYP2C19 inhibition 3
• Continue PPI throughout the DAPT period and reassess need when transitioning to single antiplatelet therapy 3, 4

Monitoring and Follow-Up

Assess for signs of re-thrombosis (recurrent arm pain, pallor, pulselessness, paresthesias) and bleeding complications (hematoma expansion, gastrointestinal bleeding) during the first 30 days 2, 7.

• Perform vascular examination at 1 week, 1 month, and 3 months to confirm brachial artery patency 7
• Consider vascular ultrasound at 1 month if clinical examination is equivocal or symptoms recur 7
• Resume antiplatelet therapy immediately if it must be interrupted for bleeding, as the thrombotic risk outweighs bleeding risk in most scenarios 3, 2

Special Considerations

If Anticoagulation Is Also Required

If the patient has atrial fibrillation or another indication for oral anticoagulation, the combination of anticoagulation plus DAPT (triple therapy) carries substantial bleeding risk 1, 3.

• Limit triple therapy to ≤1 month after thrombectomy, then transition to anticoagulation plus single antiplatelet (preferably clopidogrel) 1, 3
• Use a direct oral anticoagulant (DOAC) rather than warfarin if no contraindication exists, as DOACs have lower bleeding risk in combination with antiplatelet therapy 1
• Discontinue aspirin first when de-escalating from triple therapy, maintaining clopidogrel plus anticoagulation 1, 3

Alternative: Rivaroxaban Plus Aspirin

For patients with high atherosclerotic burden (polyvascular disease, prior cardiovascular events), consider rivaroxaban 2.5 mg twice daily plus aspirin 75–100 mg daily as an alternative to DAPT after the initial post-thrombectomy period 1, 4.

• This regimen reduces major adverse cardiovascular and limb events compared to aspirin alone in PAD patients 1, 4
• Do not use rivaroxaban 2.5 mg BID plus aspirin during the first month after thrombectomy; complete the initial DAPT course first 1, 4
• Rivaroxaban plus aspirin is contraindicated if creatinine clearance <15 mL/min or if there is prior intracranial hemorrhage 4

Common Pitfalls to Avoid

• Do not use aspirin 325 mg daily for maintenance therapy; doses >100 mg increase bleeding without improving efficacy 1, 4
• Do not substitute ticagrelor or prasugrel for clopidogrel in peripheral arterial thrombosis, as evidence supports clopidogrel specifically 1, 3
• Do not discontinue antiplatelet therapy prematurely due to minor bleeding (e.g., bruising); only major bleeding warrants interruption 1, 2
• Do not use warfarin plus antiplatelet therapy for peripheral arterial disease without another indication (e.g., mechanical valve), as this increases bleeding without reducing ischemic events 1